Prognostic implications of forkhead box protein O1 (FOXO1) and paired box 3 (PAX3) in epithelial ovarian cancer

Han, Gwan Hee; Chay, Doo Byung; Nam, Soonkeon; Cho, Hanbyoul; Chung, Joon‐Yong; Kim, Jae Hoon

doi:10.1186/s12885-019-6406-6

Cited by 16 publications

(21 citation statements)

References 50 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, forkhead box-O1 (FOXO1), one of the FOXO subtypes, has attracted attention as an antiobesity target molecule due to its diverse effects in cell cycle control and adipocyte differentiation [ 7 ]. Based on previous studies, FOXO1 was shown to be a tumor suppressor that regulates cell cycles in a variety of human cancers [ 8 , 9 ]. FOXO1 also regulates the cell cycle during adipocyte differentiation [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Lignan from Alnus japonica Inhibits Adipocyte Differentiation via Cell Cycle and FOXO1 Regulation

2020

View full text Add to dashboard Cite

In the present study, we isolated a lignan ((−)-(2R,3R)-1,4-O-diferuloylsecoisolariciresinol, DFS) from Alnus japonica and evaluated its antiobesity potential in vitro. We also determined its mechanism of action in a mouse pre-adipocyte 3T3-L1 cell line. DFS dose- and day-dependently inhibited adipogenesis by downregulation of adipogenic factors and lipid metabolism-regulating factors during adipocyte differentiation. In particular, DFS suppressed cell cycle-regulating factors and induced G0/G1 cell cycle arrest, implying that it had an inhibitory effect on mitotic clonal expansion which occurred at an early stage of adipogenesis. DFS also suppressed adipogenesis through decreasing Akt phosphorylation and increasing the level of Forkhead box protein-O1 (FOXO1). These results suggest that DFS may be a pharmacological candidate for the development of antiobesity, therapeutic, and nutraceutical products.

show abstract

Section: Introductionmentioning

confidence: 99%

Lignan from Alnus japonica Inhibits Adipocyte Differentiation via Cell Cycle and FOXO1 Regulation

2020

View full text Add to dashboard Cite

show abstract

“…For example, FOXO1 expression in cervical cancer tissues was downregulated, and in epithelial ovarian cancer (EOC) tissues was significantly highly expressed. 31 , 32 …”

Section: Discussionmentioning

confidence: 99%

The Clinical Significance and Biological Function of PCDH7 in Cervical Cancer

Shi-tong¹,

Fu²

2021

CMAR

View full text Add to dashboard Cite

Purpose Cervical cancer is a common cancerous tumor in women that is prone to recurrence and metastasis. Recently, many people have explored the role of protocadherin 7 ( PCDH7 ) in cancer and found that PCDH7 is abnormally expressed in many cancers. The purpose of this study is to explore the expression and mechanism of PCDH7 in cervical cancer and evaluate its clinical prognostic significance. Materials and Methods The expression of PCDH7 in cervical cancer and cells was measured by qRT-PCR. The relationship between PCDH7 expression and the clinical prognosis was calculated using the Kaplan–Meier method and Cox regression analyses. Effects of PCDH7 on cancer cell proliferation, migration, and invasion were studied by MTT assay and transwell assays. Results The expression of PCDH7 in cervical cancer tissues and cell lines was notably downregulated compared with the corresponding control. Low PCDH7 expression was associated with a low survival rate. PCDH7 expression was correlated with lymph node metastasis, cell differentiation, and FIGO staging. PCDH7 can be used as an independent prognostic factor for cervical cancer. Up-regulation of PCDH7 significantly inhibited the proliferation ability, migration potential, and invasion capacity of cancer cells. Conclusion PCDH7 may be used as a prognostic biomarker for cervical cancer patients.

show abstract

“…Ovarian cancer is characterized by a heterogeneous histopathology with the manifestation of dissimilar genetic and pathway alterations. Major pathways that are aberrantly altered in a range of subtypes include TP53 ( 68 , 69 ), PI3K/AKT ( 70 – 72 ), VEGF ( 73 , 74 ), EGFR ( 75 , 76 ) and FoxO signaling ( 77 ). It was significant that KEGG and Reactome pathway analyses of the DEGs upregulated in GNA12 -silenced cells directly linked GNA12 to these multiple tumor-promoting pathways.…”

Section: Discussionmentioning

confidence: 99%

Identification of GNA12‑driven gene signatures and key signaling networks in ovarian cancer

Jayaraman

Yan

et al. 2021

Oncol Lett

View full text Add to dashboard Cite

With the focus on defining the oncogenic network stimulated by lysophosphatidic acid (LPA) in ovarian cancer, the present study sought to interrogate the oncotranscriptome regulated by the LPA-mediated signaling pathway. LPA, LPA-receptor (LPAR) and LPAR-activated G protein 12 α-subunit, encoded by G protein subunit α 12 ( GNA12 ), all serve an important role in ovarian cancer progression. While the general signaling mechanism regulated by LPA/LPAR/ GNA12 has previously been characterized, the global transcriptomic network regulated by GNA12 in ovarian cancer pathophysiology remains largely unknown. To define the LPA/LPAR/ GNA12 -orchestrated oncogenic networks in ovarian cancer, transcriptomic and bioinformatical analyses were conducted using SKOV3 cells, in which the expression of GNA12 was silenced. Array analysis was performed in Agilent SurePrint G3 Human Comparative Genomic Hybridization 8×60 microarray platform. The array results were validated using Kuramochi cells. Gene and functional enrichment analyses were performed using Database for Annotation, Visualization and Integrated Discovery, Search Tool for Retrieval of Interacting Genes and Cytoscape algorithms. The results indicated a paradigm in which GNA12 drove ovarian cancer progression by upregulating a pro-tumorigenic network with AKT1, VEGFA, TGFB1, BCL2L1, STAT3 , insulin-like growth factor 1 and growth hormone releasing hormone as critical hub and/or bottleneck nodes. Moreover, GNA12 downregulated a growth-suppressive network involving proteasome 20S subunit (PSM) β6, PSM α6, PSM ATPase 5, ubiquitin conjugating enzyme E2 E1, PSM non-ATPase 10, NDUFA4 mitochondrial complex-associated, NADH:ubiquinone oxidoreductase subunit B8 and anaphase promoting complex subunit 1 as hub or bottleneck nodes. In addition to providing novel insights into the LPA/LPAR/ GNA12 -regulated oncogenic networks in ovarian cancer, the present study identified several potential nodes in this network that could be assessed for targeted therapy.

show abstract

Prognostic implications of forkhead box protein O1 (FOXO1) and paired box 3 (PAX3) in epithelial ovarian cancer

Cited by 16 publications

References 50 publications

Lignan from Alnus japonica Inhibits Adipocyte Differentiation via Cell Cycle and FOXO1 Regulation

Lignan from Alnus japonica Inhibits Adipocyte Differentiation via Cell Cycle and FOXO1 Regulation

The Clinical Significance and Biological Function of PCDH7 in Cervical Cancer

Identification of GNA12‑driven gene signatures and key signaling networks in ovarian cancer

Contact Info

Product

Resources

About